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Background: We aimed to investigate the diagnostic utility of osteocalcin (OC), undercar-
boxylated osteocalcin (ucOC), and alkaline phosphatase (ALP) in pre- and postmenopausal 
women for femoral neck, L1-4, and L2-4 bone mineral density (BMD) values by taking into 
consideration their age, body mass index (BMI), and menopausal status. 
Methods: Premenopausal (N=40) and postmenopausal cases (N=42) were classified as 
25-34 or 35-45 yr of age and within the first 5 yr or 5 yr or more after the onset of meno-
pause, respectively. 
Results: Among the groups, statistical differences were found for age, BMI, OC, ucOC, 
ALP, femoral neck BMD, L1-4 BMD, and L2-4 BMD. The highest serum OC, ucOC, and 
ALP levels were observed in cases within the first 5 yr after the onset of menopause, prob-
ably due to a more rapid bone turnover rate. The best predictors for the femoral neck os-
teoporosis were ALP, OC, and calcium (areas under the ROC curve [AUC]=0.882, 0.829, 
and 0.761, respectively), and those for L1-4 and L2-4 osteoporosis were OC, ALP, and ucOC 
(AUC=0.949, 0.873, and 0.845; and 0.866, 0.819, and 0.814, respectively). Multiple logis-
tic regression analysis revealed that the most discriminative parameter for osteoporosis 
was OC. 
Conclusions: These results indicate that serum OC levels, with or without ucOC and ALP, 
may be useful to monitor follow-up changes that currently cannot be assessed with BMD 
and to diagnose femoral neck, L1-4 spine, and L2-4 spine osteoporosis.
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INTRODUCTION
Osteoporosis (OP), a metabolic bone disease characterized by 
low bone mass and the deterioration of bone microarchitecture, 
has become more important as the average life span has in-
creased [1]. OP occurs as a result of a pause in new bone for-
mation and/or increased bone resorption. The imbalance be-
tween bone formation and resorption parallels the decreased 
estrogen production due to aging and/or menopause [2, 3]. Early 
diagnosis of OP by bone mineral density (BMD) is extremely im-
portant since treatment in the advanced phase of OP is not suf-
ficient to prevent bone fracture. Currently, dual energy X-ray ab-
sorptiometry (DXA) is the gold standard diagnostic tool for BMD 
measurement [4, 5]. However, changes in BMD occur over a Atalay S, et al.
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long period, and it is generally not useful to repeat BMD mea-
surement until the end of the first or second yr of therapy [1, 5]. 
Determination of the bone turnover rate using biochemical 
markers is used to differentiate primary OP from secondary OP, 
identify cases at high risk of bone fracture, select treatment type, 
and in particular, evaluate the effectiveness of antiresorptive 
therapy [6, 7].
  Osteocalcin (OC), a bone-specific protein synthesized by the 
osteoblasts in bone, is the major non-collagen protein in the 
bone matrix. It has a molecular weight of 5,800 Da and contains 
49 amino acids, including 3 gamma carboxyl glutamic acid resi-
dues that facilitate the binding of OC to hydroxyapatite in bone 
[8]. The serum OC level, a sensitive marker of bone production, 
is associated with a high bone turnover rate and decreased 
BMD, and correlates well with histomorphometric indices of 
bone formation [9]. 
  The fraction of OC that has undergone imperfect gamma-car-
boxylation is referred to as undercarboxylated osteocalcin (ucOC). 
Serum ucOC concentrations are a marker of both bone turnover 
and vitamin K status in bone [10]. Low dietary intake of vitamin 
K is related to elevated serum ucOC levels. Moreover, increased 
serum ucOC levels have been associated with an increased risk 
of hip fracture [11], and low BMD of the hip and spine in pre- 
and postmenopausal women [12].
  Markers of bone turnover are considered useful diagnostic 
tools for the evaluation of bone formation and resorption. We 
measured serum OC and total serum alkaline phosphatase (ALP) 
activity as markers of bone formation. The objectives of this 
study were to determine the diagnostic utility of OC, ucOC, and 
ALP for predicting femoral neck, lumbar 1-4 (L1-4) spine, and 
lumbar 2-4 (L2-4) spine osteoporosis by taking into consider-
ation age, body mass index (BMI), and menopausal status; in-
vestigate the association between serum OC, ucOC, and ALP 
levels with femoral neck, L1-4 spine, and L2-4 spine BMD val-
ues; determine the differences in serum OC, ucOC, and ALP 
concentrations between pre- and postmenopausal women of 
varying ages; and predict which patient group has the most 
rapid bone turnover rate. 
METHODS
1. Study population
This study was accepted by the local ethics committee of Hay-
darpasa Numune Teaching and Research Hospital, and all in-
vestigations were carried out in accordance with the criteria of 
Helsinki II Declaration. Postmenopausal volunteers were chosen 
from the general ambulatory population of the surrounding com-
munity. Participants were questioned about their medical history 
and were excluded if they were taking oral contraceptives, on 
any special diet, using any drug that affects bone metabolism, 
smoking, exercising regularly, or had any metabolic disease or 
nutritional disorder that could affect bone metabolism. A control 
group of 40 subjects was selected from the hospital staff and 
their relatives who had no known disease or complaint, and was 
divided into 2 groups, 25-34 yr of age (group I, N=20) and 35-
45 yr of age (group II, N=20). While 20 of the postmenopausal 
cases were within the first 5 yr after the onset of menopause 
(group III), the remaining cases (N=22) were 5 yr or more after 
the onset of menopause (group IV). Menopausal subjects were 
identified by a gynecologist based on the criteria described by 
WHO [13].
2. Biochemical parameters
Fasting blood samples were taken from all participants in plain 
tubes between 08:00 and 09:00 AM. Blood samples were centri-
fuged for 30 min at 1,300×g to separate the serum. ALP, cal-
cium, and phosphorus were immediately analyzed by standard 
laboratory methods. Serum samples were stored at -20°C, and 
then OC, ucOC, and total acid phosphatase activity were ana-
lyzed on the same day that the samples were thawed at room 
temperature. 
  Osteocalcin was measured by an electrochemiluminescence 
immunoassay (E170 Modular System; Roche, Mannheim, Ger-
many). OC and ucOC in serum were differentiated using BaSO4 
powder as previously described by Sokoll et al. [14]. In this 
method, measurements were performed by incrementally in-
creasing the amount of BaSO4 in the same serum pool in order 
to determine the optimum BaSO4 concentration that does not 
permit nonspecific binding, but binds all γ-carboxy glutamate 
residues. In an Eppendorf tube, 300 µL of serum was mixed with 
100 mg of BaSO4 powder for 30 min at 4°C. It was then centri-
fuged for 2 min at 10,000×g and OC precipitated. Using the su-
pernatant, ucOC was determined by the OC measurement 
method. The lower limits of detection for OC and ucOC were 0.5 
ng/mL and 0.09 ng/mL, respectively. To improve the sensitivity 
of ucOC, the ucOC/OC ratio was also assessed with intact OC 
level correction.
3. Bone mineral density measurement
BMD was measured in all individuals at the femoral neck of the 
left leg, L1-4 spine, and L2-4 spine using DXA (Lunar DPX-L; 
Lunar, Madison, WI, USA). Osteoporosis and osteopenia were Atalay S, et al.
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established according to the T score; a T score above -1 was 
accepted as normal bone mass, between -1 and -2.5 was con-
sidered osteopenia, and below -2.5 was considered osteoporosis 
[13]. BMD was measured on the same day that blood samples 
were taken for the biochemical parameters. 
4. Statistical analysis
All of the statistical analyses were performed using the SPSS 
version 15 software package for Windows (SPSS Inc., Chicago, 
IL, USA) and MedCalc software for Windows (MedCalc Software 
Inc., Mariakerke, Belgium). Kolmogorov Smirnov analysis was 
performed to evaluate whether the distribution of values was 
normal or not. If distribution was normal, one-way ANOVA and 
Tukey’s HSD tests were used for intergroup comparison to de-
termine the cause of the group difference. In contrast, Kruskal-
Wallis Variance analysis was performed to demonstrate the dif-
ferences among the 3 groups, and the Mann-Whitney U-test was 
used for pairwise comparison of the median values of groups to 
determine statistical significance. Pearson or Spearman correla-
tion coefficients were preferred according to the distribution of 
variables to assess the association between parameters. The di-
agnostic accuracy of the evaluated variables was assessed by 
calculating the areas under the ROC curves. We have performed 
the statistical analysis for the comparison of ROC curves using 
MedCalc software. Multiple logistic regression analyses were 
carried out to determine which single parameter is most discrim-
inative for OP. For each outcome, the models included terms for 
age, BMI, OC, ucOC, total acid phosphatase, ALP, calcium, and 
phosphorus. All of the reported P values were based on 2-sided 
tests, and those less than 0.05 were considered statistically sig-
nificant. 
RESULTS
Subject characteristics are summarized in Table 1. The ages of 
the postmenopausal women ranged from 43 to 74 yr old (mean
±SD: 58±8), while the premenopausal women’s ages ranged 
from 25 to 44 yr old (mean±SD: 35±6). Two and six osteopo-
rotic women were observed in the first 5 yr after menopause 
group, and more than 5 yr after menopause group, respectively. 
The mean serum OC, ucOC, and ALP concentrations were sig-
nificantly higher in postmenopausal women than in premeno-
pausal women (Table 1). Serum OC and ucOC concentrations 
differed significantly among the groups (P=0.012 and P=0.003, 
respectively). Significant difference was observed between group 
III and group II for OC (Fig. 1, P=0.001), and between group III 
and both group II (P=0.002) and group I (P=0.038) for ucOC. 
The ucOC/OC ratio differed slightly, although it was not statisti-
Table 1. Comparison of parameters according to menopausal status*
Variable
Premenopausal group (N=40) Postmenopausal group (N=42)
P Group I
25-34 yr of age
(N=20)
Group II
35-45 yr of age
(N=20)
Group III
1-5 yr after menopause
(N=20)
Group IV
≥5 yr after menopause
(N=22)
Age (yr)
† 30±4 40±3 53±7 63±7 <0.001
BMI 21.2±1.7
‡ 24.6±2.9 28.9±4.1 28.5±4.0 <0.001
OC (ng/mL) 24.9±6.3 21.7±9.5 31.8±12.0
§ 28.3±10.4 0.012
ucOC (ng/mL) 1.48±0.52 1.21±0.72 2.25±1.16
II 1.71±0.92 0.003
ucOC/OC ratio (%) 5.9±1.3 5.5±1.5 7.0±2.7 5.9±2.0 0.072
TACP (IU/L) 2.42±0.58 2.69±0.76 2.86±0.51 2.66±0.44 0.129
ALP (IU/L) 56±13 65±13 92±18
¶ 90±21** <0.001
Calcium (mg/dL) 9.7±0.3 9.5±0.3 9.7±0.4 9.7±0.4 0.089
Phosphorus (mg/dL) 3.6±0.4 3.6±0.4 3.5±0.4 3.5±0.3 0.838
BMD, Femoral neck (g/cm
2) 0.957±0.115 0.950±0.136 0.880±0.122 0.810±0.110
†† 0.002
BMD, L1-4 (g/cm




2) 1.205 + 0.131 1.214 + 0.147 1.043 + 0.155
II II 0.989 +0.132
¶¶ <0.001
*Variables are expressed as arithmetic mean±SD; 
†P values were <0.001 for all of the pairwise groups; 
‡P=0.011 vs. group II, P=0.005 vs. group III, P<0.001 
vs. group III and group IV; 
§P=0.001 vs. group II; 
IIP=0.038 vs. group I, P=0.002 vs. group II; 
¶P<0.001 vs. group I and group II; **P< 0.001 vs. group I 
and group II; 
††P=0.014 vs. group I, P=0.006 vs. group II; 
‡‡P=0.02 vs. group I, P=0.002 vs. group II; 
§§P<0.001 vs. group I and group II; 
II IIP=0.03 vs. 
group I, P=0.006 vs. group II; 
¶¶P<0.001 vs. group I and group II.
Abbreviations: OC, osteocalcin; ucOC, undercarboxylated osteocalcin; TACP, total acid phosphatase; ALP, alkaline phosphatase; BMD, bone mineral density.Atalay S, et al.
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cally significant (P=0.072). 
  Comparison showed that the BMD values differed significantly 
among the groups (Table 1 and Fig. 2). Serum OC levels for the 
groups based on the T score of femoral neck, L1-4 spine, and 
L2-4 spine BMD are shown in Fig. 3. Comparisons of the evalu-
ated parameters among the groups according to the BMD T 
score are shown in Table 2-4. Femoral neck BMD values were 
inversely correlated with age and serum OC level (r=-0.358, P= 
0.004 and r=-0.296, P=0.016, respectively). Highly significant 
inverse correlations were observed between L1-4 spine BMD 
values and age, serum OC, ucOC, and ALP values (r=-0.425, 
P<0.001; r=-0.431, P<0.001; r=-0.349, P=0.001; and r=-0.393, 
P<0.001, respectively). In addition, L2-4 spine BMD values were 
inversely correlated with age, and serum OC, ucOC, and ALP 
levels (r=-0.459, P<0.001; r=-0.423, P<0.001; r=-0.299, P= 
Fig. 1. Distribution of serum osteocalcin levels in 4 different groups 




























     25-34 yr                  35-45 yr                1-5 yr after            >5 yr after
      of age                      of age                  menopause            menopause
*
Fig. 3. Distribution of serum osteocalcin levels in normal, osteope-
nia and osteoporosis groups. *, P=0.017 vs. the normal group; 
†, 
P=0.029 vs. the normal group; 
‡, P=0.001 vs. the normal group 
and P=0.011 vs. the osteopenia group; 
§, P<0.001 vs. the normal 
group and P=0.004 vs. the osteopenia group; *
†, P<0.001 vs. the 









































Fig. 2. Distribution of femoral neck, L1-4 spine, and L2-4 spine 
BMD values in 4 different groups of menopausal status. *, P=0.02 
vs. the 25-34 yr age-group and P=0.002 vs. the 35-45 yr age-
group; 
†, P=0.03 vs. the 25-34 yr age-group and P=0.006 vs. the 
35-45 yr age-group; 
‡, P=0.014 vs. the 25-34 yr age-group and 
P=0.006 vs. the 35-45 yr age-group; 
§, P<0.001 vs. the 25-34 yr 
age-group and the 35-45 yr age-group; *
†, P<0.001 vs. the 25-34 
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Age (yr) 44 (38-56) 56 (42-65) 58 (52-66)
† 0.037
BMI 26.2 (23.5-30.5) 25.6 (22.4-28.8) 25.8 (24.1-27.5) 0.587
OC (ng/mL) 23.9 (19.5-30.3) 26.9 (17.9-31.4) 43.5 (29.1-55.7)
‡ 0.028
ucOC (ng/mL) 1.38 (0.97-2.16) 1.42 (1.00-1.71) 2.17 (1.41-4.12)
§ 0.050
ucOC/OC ratio (%) 6.0 (5.0-6.8) 5.7 (4.4-6.7) 5.7 (4.6-7.0) 0.687
TACP (IU/L) 2.7 (2.4-3.0) 2.7 (2.1-3.0) 2.9 (2.4-3.4) 0.760
ALP (IU/L) 68 (55-88) 80 (62-89) 107 (94-129)
II 0.005
Calcium (mg/dL) 9.7 (9.4-9.9) 9.5 (9.3-9.8) 10.0 (9.7-10.2) 0.080
Phosphorus (mg/dL) 3.6 (3.4-3.9) 3.5 (3.3-3.8) 3.6 (3.0-3.8) 0.818
*Variables are expressed as median (25th-75th interquartile range); 
†P=0.026 vs. the normal group; 
‡P=0.001 vs. the normal group, P=0.011 vs. the os-
teopenia group; 
§P=0.050 vs. the osteopenia group; 
IIP=0.002 vs. the normal group, P=0.004 vs. the osreopenia group. 
Abbreviations: BMD, bone mineral density; BMI, body mass index; OC, osteocalcin; ucOC, undercarboxylated osteocalcin; TACP, total acid phosphatase; ALP, 
alkaline phosphatase.Atalay S, et al.
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0.015; and r=-0.393, P<0.001, respectively). 
1. ROC analysis 
ROC curve analysis was used to determine the discriminative 
power of each evaluated parameter for osteoporosis. The area 
under the ROC curves (AUC) based on femoral neck osteoporo-
sis (AUC=0.882, P=0.002 for ALP; AUC=0.829, P=0.008 for 
OC; AUC=0.761, P=0.034 for calcium), L1-4 spine osteoporosis 
(AUC=0.949, P=0.003 for OC; AUC=0.873, P=0.012 for ALP; 
AUC=0.845, P=0.021 for ucOC), and L2-4 spine osteoporosis 
(AUC=0.866, P=0.003 for OC; AUC=0.819, P=0.010 for ALP; 
AUC=0.814, P=0.011 for ucOC) were calculated separately for 
significant variables (Fig. 4). There were no statistically significant 
differences in comparison of the ROC curves between pairwise 
markers except for OC and ucOC to determine the OP. This sig-
nificance was observed in L1-4 OP (P=0.007). 
2. Predictors of osteoporosis 
A multiple logistic regression analysis revealed that OC has the 
highest predictive value for OP (P=0.029, P<0.001, and P= 
0.002 for femoral neck, L1-4 spine osteoporosis, and L2-4 spine 
osteoporosis, respectively) when all of the evaluated biochemi-
cal parameters, age, BMI, and menopausal status of women 
were included in the equation. 








Age (yr) 42 (38-55) 57 (49-66)
† 61 (54-65)
‡ 0.004
BMI 25.7 (22.1-29.4) 27.3 (23.4-29.8) 25.8 (24.4-27.7) 0.815
OC (ng/mL) 22.5 (18.2-28.5) 28.7 (20.7-32.7)
§ 43.5 (36.5-64.0)
II 0.001
ucOC (ng/mL) 1.31 (0.86-1.75) 1.55 (1.30-2.53)
¶ 2.19 (2.11-4.02)** 0.006
ucOC/OC ratio (%) 5.8 (4.7-6.6) 6.0 (4.8-7.5) 5.8 (4.8-6.5) 0.493
TACP (IU/L) 2.6 (2.2-3.0) 2.8 (2.5-3.1) 2.9 (2.2-3.3) 0.193
ALP (IU/L) 67 (54-87) 84 (65-97)
†† 114 (88-130)
‡‡ 0.004
Calcium (mg/dL) 9.7 (9.3-9.9) 9.6 (9.4-9.8) 9.9 (9.4-10.2) 0.643
Phosphorus (mg/dL) 3.6 (3.3-3.9) 3.6 (3.4-3.8) 3.3 (2.5-3.5) 0.178
*Variables are expressed as median (25-75th interquartile range); 
†P=0.004 vs. the normal group; 
‡P=0.031 vs. the normal group; 
§P=0.017 vs. the normal 
group; 
IIP<0.001 vs. the normal group, P=0.004 vs. the osteopenia group; 
¶P=0.021 vs. the normal group; 
**P=0.010 vs. the normal group; 
††P=0.023 
versus the normal group; 
‡‡P=0.005 vs. the normal group, P=0.038 vs. the osteopenia group.
Abbreviations: BMD, bone mineral density; BMI, body mass index; OC, osteocalcin; ucOC, undercarboxylated osteocalcin; TACP, total acid phosphatase; 
ALP, alkaline phosphatase. 








Age (yr) 42 (38-55) 57 (49-68)
† 59 (52-64)
‡ 0.005
BMI 25.7 (22.1-29.4) 27.3 (23.1-30.0) 25.8 (24.4-28.4) 0.847
OC (ng/mL) 22.5 (18.2-28.5) 28.7 (20.0-33.5)
§ 36.7 (30.9-54.6)
II 0.001
ucOC (ng/mL) 1.31 (0.86-1.75) 1.55 (1.29-2.30)
¶ 2.19 (1.95-3.20)** 0.005
ucOC/OC ratio (%) 5.8 (4.7-6.6) 6.0 (5.0-7.3) 5.8 (4.6-7.6) 0.561
TACP (IU/L) 2.6 (2.2-3.0) 2.8 (2.5-3.1) 3.1 (2.5-3.4) 0.128
ALP (IU/L) 67 (54-87) 84 (62-95)
†† 104 (81-129)
‡‡ 0.004
Calcium (mg/dL) 9.7 (9.3-9.9) 9.6 (9.4-9.8) 10.0 (9.5-10.2) 0.222
Phosphorus (mg/dL) 3.6 (3.3-3.9) 3.6 (3.4-3.8) 3.5 (3.0-3.8) 0.671
*Variables are expressed as median (25-75th interquartile range); 
†P=0.007 vs. the normal group; 
‡P=0.014 vs. the normal group; 
§P=0.029 vs. the normal 
group; 
IIP<0.001 vs. the normal group, P=0.029 vs. the osteopenia group; 
¶P=0.037 vs. the normal group; 
**P=0.004 vs. the normal group; 
††P=0.034 vs. 
the normal group; 
‡‡P=0.004 vs. the normal group, P=0.050 vs. the osteopenias group. 
Abbreviations: BMD, bone mineral density; BMI, body mass index; OC, osteocalcin; ucOC, undercarboxylated osteocalcin; TACP, total acid phosphatase; 




In the present study, serum OC, ucOC, and ALP concentrations 
were significantly higher in women in the postmenopausal group 
than in those in the premenopausal group. The highest serum 
OC, ucOC, and ALP concentrations were observed in patients 
within 1-5 yr after the onset of menopause, probably due to in-
creased bone turnover rate. Osteocalcin, with or without ucOC 
and ALP, could be a useful diagnostic tool to select patients with 
probable femoral neck, L1-4 spine, or L2-4 spine osteoporosis 
for BMD measurement.
  BMD is the most valuable diagnostic tool to differentiate pa-
tients with OP from healthy individuals. However, only changes 
that take place over long periods of time can be measured by 
BMD, and changes due to therapy cannot be immediately ob-
served. Biochemical bone markers are non-invasive and less 
expensive diagnostic tools that are beneficial for diagnosis and 
treatment follow-up of metabolic bone diseases. In addition, 
while BMD measurements reflect the static status of bone tis-
sue, biochemical bone markers show the dynamic status [1, 5, 
14, 15]. Therefore, using BMD measurements together with 
these markers can make the diagnosis, risk evaluation, and 
therapy of OP more effective.
  Osteocalcin is a product of osteoblasts that is considered a 
marker of bone formation [9]. However, osteocalcin is also re-
leased from the bone matrix into blood during bone resorption, 
suggesting that osteocalcin is also a marker of bone turnover 
[16]. Therefore, the higher serum osteocalcin levels and ALP 
Fig. 4. ROC curve analysis of biochemical bone markers for osteo-
porosis. (A) femoral neck osteoporosis (AUC=0.882, P=0.002 for 
ALP; AUC=0.829, P=0.008 for OC; AUC=0.761, P=0.034 for cal-
cium), (B) L1-4 spine osteoporosis (AUC=0.949, P=0.003 for OC; 
AUC=0.873, P=0.012 for ALP; AUC=0.845, P=0.021 for ucOC), 
and (C) L2-4 spine osteoporosis (AUC=0.866, P=0.003 for OC; 
AUC=0.819, P=0.010 for ALP; AUC=0.814, P=0.011 for ucOC). 
Abbreviations: AUC, area under the curve; ALP, alkaline phosphatase; 
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observed in women within the first 5 yr after the onset of meno-
pause may reflect an increased bone turnover rate rather than 
simply increased bone formation, and thus may be associated 
with an increased risk of bone fracture and OP.
  Although the amount of ucOC is considered a sensitive mea-
sure of vitamin K status in bone, we did not measure the con-
centration of vitamin K. However, according to the medical his-
tory of our study population, they seemed to have healthy vita-
min K statuses. In addition, vitamin K deficiency increases with 
age; but, in the present study, older (group IV) patients had lower 
ucOC levels than younger (group III) patients, although there 
was also no significant positive correlation between ucOC and 
age. Therefore, we did not consider vitamin K deficiency in our 
study population. 
  Within a woman’s life span, 75% of total bone loss is seen 
during the postmenopausal period due to estrogen deficiency 
(52-66%) and aging (34-48%). Bone loss in early postmeno-
pausal women is more rapid due to more rapid osteoporosis, 
and 30% of total body bone mass is lost in the first 15-20 yr after 
the onset of menopause [13, 17, 18]. Based on our findings, the 
rate of bone loss in postmenopausal women seems to be greater 
within the first 5 yr after the onset of menopause. OC, ucOC, the 
ucOC/OC ratio, and ALP concentration were significantly higher 
in osteoporotic women compared with non-osteoporotic women. 
Therefore, these results could influence their corresponding 
therapeutic strategies, by adding antiresorptive drugs for peri- 
and early postmenopausal women. In the current study, we per-
formed a multiple logistic regression analysis to control for prob-
able confounding variables such as BMD, age, and the meno-
pausal status of women. According to the ROC and multiple lo-
gistic regression analyses, OC may be a useful diagnostic tool to 
select patients with probable OP and to effectively personalize 
their therapy. 
  Plantalech et al. [19] reported that total OC and ucOC serum 
levels were significantly higher in postmenopausal women than 
in premenopausal women, as was observed in our study. We 
considered that while the bone turnover rate is steady in pre-
menopausal women, it was induced during the postmenopausal 
period; thus, OC and ALP concentrations were elevated. 
  Serum ucOC is expressed as a percentage of total OC. This 
ratio seemed to be increased in postmenopausal women com-
pared with premenopausal women; but, the increase was not 
statistically significant (P=0.072). Szulc et al. [20] stated that 
ucOC could be a predictor of hip fracture risk in elderly women, 
because serum ucOC levels were higher in 70-101-yr-old women 
than in a younger premenopausal control group, and 23% had 
values greater than the normal premenopausal range. In a study 
of women aged 20-90 yr, Knapen et al. [21] observed a strong 
inverse relationship between serum ucOC/OC ratio and femoral 
neck BMD levels during the first 10 yr after the onset of meno-
pause; however, we did not observe such a relationship. Yasui 
et al. [22] also did not find an association between serum ucOC 
and L1-4 spine BMD; however, they observed higher ucOC lev-
els in perimenopausal women than in others. In the present 
study, the difference in this ratio among the groups was not sig-
nificant, because there was a fewer number of patients in each 
subgroup. 
  The present study has some limitations. First, the number of 
the women with osteoporosis was low. Second, we did not mea-
sure other specific bone turnover markers that could support 
the importance of the first 5 yr after the onset of menopause for 
OP and OP therapy.
  In conclusion, the observations in this study suggest that mea-
suring serum osteocalcin concentration may be helpful to moni-
tor follow-up changes that currently cannot be assessed with 
BMD, and the elevation of osteocalcin levels could be a more 
efficient method to detect patients with fast bone turnover rates 
after the onset of menopause. Determination of osteocalcin lev-
els in serum could be helpful to predict probable femoral neck, 
L1-4 spine, and L2-4 spine osteoporosis before performing BMD. 
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